What should a drug company do if it spends millions of dollars on a compound and it doesn’t do anything? Easy: (Click on the panel to see the whole cartoon.) In fact, I’m surprised more pharmaceutical companies don’t do this…
Yesterday, I wrote a post about what fellow ScienceBlogger Isis would term “hot, hot science.” As much as I love science like that, writing such posts is a lot of work and takes considerably longer than my run-of-the-mill bit of insolent brilliance. Often, after writing an analysis of a peer-reviewed paper like that, I need […]
Share this:
Three years ago, I wrote about what I considered to be a fascinating and promising approach to understanding tumor biology. This method involved understanding that tumors are in general made up of a heterogeneous collection of cells. Using this knowledge, it is possible to apply evolutionary principles to cancer, treating a tumor as, in essence, […]
Share this:
These days, I don’t often participate in mass bloggings about various topics, at least not as much as I used to. I can’t say if it’s laziness or being jaded after having blogged on nearly a daily basis for over four years now, or an ornery tendency to want to go my own way these […]
Share this:
Last week I wrote a bit about what I’ve been tempted to call Oprah’s War on Science but settled for the title of a documentary called The Oprah Effect. The reason, as I have mentioned before, is that arguably there is no single person who does more to promote pseudoscientific and dubious health practices than […]
